Loading clinical trials...

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project | Clinical Trials | Clareo Health

RECRUITING

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

NCT06156774•Fondazione Italiana Linfomi - ETS

View on ClinicalTrials.gov

Summary

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients (≥ 18 years old).
•Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug
•Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART
•Written informed consent voluntarily provided

Exclusion Criteria

•Patients not fulfilling the eligibility criteria

Locations (21)

A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia

Alessandria, Italy

AOU Ospedali Riuniti - Clinica di Ematologia

Ancona, Italy

Azienda Ospedaliera S .Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

Avellino, Italy

IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati

Aviano, Italy

ASST Spedali Civili di Brescia - S.C. Ematologia

Brescia, Italy

Ospedale di Castelfranco Veneto - Oncoematologia IOV

Castelfranco Veneto, Italy

Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

Florence, Italy

ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

Milan, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia

Milan, Italy

Istituto Scientifico San Raffaele - Unità Linfomi - Dipartimento Oncoematologia

Milan, Italy

Key Dates

Start Date

April 18, 2024

Primary Completion Date

July 1, 2026

Completion Date

July 1, 2026

Last Updated

December 8, 2025

Enrollment

130

ESTIMATED participants

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

Chimeric Antigen Receptor T-cells (CAR-T) therapy

OTHER

Contacts

Uffici Studi FIL

CONTACT

+390131033153 startup@filinf.it

Uffici Studi FIL

CONTACT

+390599769910 gestionestudi@filinf.it

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT04094142

Non-hodgkin Lymphoma,B Cell

View study

UNKNOWNPHASE1/PHASE2

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

NCT04897477

Non-hodgkin Lymphoma,B Cell

View study

UNKNOWNPHASE1/PHASE2

CART-19 Immunotherapy in Mantle Cell Lymphoma

NCT02081937

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions